Abstract. RTS,S is a novel pre-erythrocytic malaria vaccine based on the circumsporozoite surface protein (CSP) of Plasmodium falciparum linked to hepatitis B surface antigen (HBs) and combined with a novel adjuvant system (SBAS2). We have conducted a Phase I trial with three doses of this vaccine given at 0, 1, and 6 months to 20 semiimmune, adult, male volunteers in The Gambia to assess its safety and immunogenicity. Eighteen of the 20 volunteers completed the study. There were no clinically significant local or systemic adverse events following each vaccination. Hematologic and biochemical indices before and two weeks after each vaccination showed no evidence of toxicity. Antibody titers to both CSP and HBs showed a significant increase after vaccination; these were the largest after the third dose. We conclude that the RTS,S/SBAS2 vaccine induces no significant toxicity in this semi-immune population and produces significant increases in antibody titers to CSP.
Immunity to malaria is poorly understood but is acquired gradually by people living in malaria-endemic parts of the world following repeated infections, but at a cost. Plasmodium falciparum malaria is responsible for the deaths of approximately 2,500,000 people each year, and most of these deaths occur in sub-Saharan Africa. 1 While interventions such as the use of insecticide-treated bed nets may reduce the mortality and morbidity associated with the disease, the sustainability of such an intervention has been questioned. The importance of an effective vaccine against P. falciparum malaria, to be used in conjunction with other control measures, cannot be over-emphasized.
The only previous candidate malaria vaccine to enter Phase III field trials in endemic areas is SPf66, a vaccine targeting primarily the blood stage of the parasite. While the results of the first trials with this vaccine in Columbia 2 and Tanzania 3 were encouraging, subsequent trials in both The Gambia 4 and Thailand 5 showed that the efficacy of the vaccine was minimal. A novel vaccine candidate, designated RTS,S/SBAS2, was developed recently by SmithKline Beecham Biologicals (Rixensart, Belgium) and evaluated in phase I/IIa clinical studies in collaboration with the Walter Reed Army Institute of Research (WRAIR). This vaccine targets the pre-erythrocytic stage of the parasite. In human challenge studies performed at WRAIR, one particular formulation of this vaccine protected six of seven malaria-naïve volunteers against sporozoite challenge with a homologous NF54 strain of P. falciparum (clone 3D7) delivered via the bites of laboratory-reared mosquitoes. This result was statistically significant. 6 In preparation for a field trial with this vaccine formulation, with efficacy as the principal endpoint, we have conducted an open Phase I trial with three doses of RTS,S/ SBAS2 given over a six-month period to 20 adult male volunteers in The Gambia to determine its safety, tolerability, and immunogenicity.
MATERIALS AND METHODS
Vaccine. The RTS,S/SBAS2 vaccine consists of a recombinant DNA produced antigen derived from the circumsporozoite surface protein (CSP) of the NF54 strain (clone 3D7) of P. falciparum fused to hepatitis B surface antigen (HBs), and a novel adjuvant system, designated SBAS2. The antigen contains the conserved, central repeat (NANP) sequence derived from CSP and includes the entire carboxy terminal, non-repetitive region of the molecule except the hydrophobic anchor sequence. The adjuvant system (SBAS2) consists of an oil-in-water emulsion combined with two immunostimulants: monophosphoryl Lipid A and a saponin derivative known as QS-21. Vaccine was prepared in single dose (0.5 ml) vials from a single batch according to Good Manufacturing Practice by SmithKline Beecham Biologicals before shipment to The Gambia. The cold chain was maintained and monitored until vaccine administration. Vaccine was given at 0, 1, and 6 months.
Volunteers. Malaria in The Gambia is highly seasonal, occurring principally during the wet season from July to November. The study was conducted between November 1997 and June 1998. Volunteers were recruited from the village of Bakau, a suburban area on the coast of The Gambia. Previous studies have estimated the entomologic inoculation rate (EIR) for this area of The Gambia to be approximately 0.1 infectious bite per person per year. 7 However, many of the volunteers traveled regularly to other parts of The Gambia with higher EIRs, up to 10 infectious bites per person per year. These individuals would therefore have some immunity to malaria, in contrast to the malaria-naive subjects included in the challenge studies.
Each volunteer gave informed written consent to participate in the study, which was approved by the Joint Medical Research Council/Gambian Government Ethical Committee and performed according to standard Good Clinical Practice. Before enrollment, each volunteer had a thorough medical examination to exclude any clinically significant pathology and was screened for any underlying hematologic (complete blood count), renal (serum creatinine and urinalysis), or hepatic (serum alanine aminotransferase [ALT]) dysfunction.
Twenty healthy male volunteers between 18 and 45 years of age were recruited. A total of 30 volunteers were screened. One was excluded because of clinically significant aortic valve disease; one because of hypertension; one because he was clinically older than his reported 45 years; one because he traveled away from the study site immediately after screening; and six because they withdrew consent between screening and the first dose of vaccination. None of these 10 volunteers received any dose of the RTS,S/SBAS2 vaccine.
The study was monitored throughout by an independent Data Safety Monitoring Committee (DSMC) based both in The Gambia and in London.
Vaccination procedure and follow-up. Each dose (0.5 ml) of vaccine was given by deep intra-muscular injection into the body of alternating left and right deltoid muscles. Each volunteer was kept under observation for 1 hr after each vaccination. Pulse rate, blood pressure, and axillary temperature were recorded immediately before and 60 min after each dose; each volunteer was then visited at home daily for at least three days. On each of these occasions, each volunteer was asked about any local (swelling, pain at the injection site, or limited arm motion) or systemic (fever, headache, malaise, myalgia, joint pain, or nausea) adverse events and had their axillary temperature recorded. These data were recorded onto standard proforma by a single individual using a standardized scoring system (0 ϭ none; 1 ϭ mild, easily tolerated and does not interfere with normal daily activities; 2 ϭ moderate, sufficiently severe to interfere with normal daily activities; 3 ϭ severe, preventing normal daily activities). Local adverse events were always considered to be related to vaccination; for general (systemic) adverse events the relationship to vaccination was assessed by the principal investigator (JFD) as being either probably, suspected, unlikely or not related to vaccination.
For those volunteers whose symptoms persisted beyond three days, each was visited daily until the symptoms resolved. In addition, any adverse event experienced by the volunteers within 30 days of vaccination was recorded and its relationship to vaccination was assessed by the principal investigator using the same system as above.
Laboratory analysis. Each volunteer had blood taken from the ante-cubital vein on seven occasions: at screening (day Ϫ28 to Ϫ7); at the time of dose 1 (day 0); two weeks after dose 1 (day 14); at the time of dose 2 (day 28); two weeks after dose 2 (day 42); two weeks before dose 3 (day 166); and two weeks after dose 3 (day 194). The total volume of blood taken from any volunteer did not exceed 80 ml.
Hematology. Complete blood counts were measured at screening and on days 14, 42, 166, and 194 using a Celloscope 1260 (Analysis Instrument AB, Bromma, Sweden). For the purposes of the trial, a hemoglobin concentration greater than 11.0 gm/dl, a white blood cell count between 3.5 and 11 ϫ 10 9 cells/L, and a platelet count Ͼ 150 ϫ 10 9 / L were considered normal.
Biochemistry. Serum creatinine (mol/L) and ALT (IU/L) concentrations were measured at the same timepoints using a serum chemistry analyzer (Cobas Mira; ABX Diagnostics, London, United Kingdom). Serum creatinine concentrations Ͼ 120 mol/L and ALT concentrations Ͼ 42 IU/L were considered abnormal.
Malaria smears. Duplicate blood films were prepared on each occasion that blood was taken, stained with Giemsa, and 200 high-power fields (hpf) were read by two experienced slide readers at a final magnification of ϫ 1,000.
Serology. The antibody response to the tetrapeptide (NANP) repeat of CSP was measured on days 0, 28, 42, 166, and 194 using a specific ELISA using plate-adsorbed R32LR antigen with a standard reference antibody as a control. Concentrations of antibody to HBs were measured on samples taken at the same timepoints using a commercial (Abbott Laboratories, Abbott Park, IL) radioimmunoassay. In addition, HBs was measured by reverse passive hemagglutination (Murex Diagnostics, Ltd., Dartford, Kent, United Kingdom) at screening (day Ϫ28 to Ϫ7) and after the third dose of vaccine (day 194). Hepatitis B viral DNA was measured in HBs-positive chronic carriers by a polymerase chain reaction-based method.
RESULTS

Safety.
Eighteen of 20 volunteers completed the study protocol. One was excluded on the advice of the DSMC two weeks after dose 2 when he was found to have a chronic skin disease that should have precluded his enrollment. One other volunteer withdrew consent shortly before dose 3. Neither of these volunteers experienced any clinically significant symptoms.
The vaccine was well-tolerated (Table 1) . Most reported adverse events were mild, the most frequently reported being pain at the injection site. One volunteer experienced moderate limitation of arm movement (defined as an inability to abduct the shoulder Ͼ 90Њ) 24 hr after receiving the second dose, but this resolved within another 24 hr. One other volunteer experienced moderate headache after dose 2 that resolved within 24 hr. Both of these volunteers received simple analgesics. Neither the frequency nor the severity of the reported adverse events increased with repeat doses of vaccination. No severe (grade 3) adverse events were reported at any stage of the trial.
There were no adverse events after vaccination in terms of either the hematologic or the biochemical indices. One volunteer experienced a clinical attack of P. falciparum malaria (axillary temperature Ͼ 38.5ЊC, 400 trophozoites in one hpf) during the period between screening and dose 1 that resolved completely following a standard course of chloroquine and Fansidar (F. Hoffmann-La Roche, Basel, Swit- FIGURE 2. Serum concentration of antibody to hepatitis B surface antigen (mIU/ml) in response to three doses of RTS,S/SBAS2. FIGURE 1. Serum concentration of antibody to R32LR (g/ml) in response to three doses of RTS,S/SBAS2. zerland). No other episodes of clinical malaria occurred during the study. Three other blood films taken during the study showed low-level parasitemia with P. falciparum although these were not associated with disease and had cleared spontaneously by the time the second vaccine dose was given (Table 2) .
Serology. The volunteers had variable pre-existing concentrations of antibody to CSP before vaccination (Table 2) . Following vaccination, serum concentrations of antibody to R32LR, the repeat sequence of CSP, showed significant increases compared with baseline values, which were maximal after dose 3 ( Figure 1 ). Geometric mean titers on days 0, 28, 42, 166, and 194 were 1.7, 12.7, 33.1, 9.6, and 46.8 g/ml, respectively. There was no relationship between the concentration of antibody to CSP at enrollment and the concentration at the end of the study (r ϭ 0.28, P Ͼ 0.2).
Concentrations of antibody to HBs showed a similar picture (Table 3 and Figure 2 ) with geometric mean titers of 26, 169, 1,187, 308, and 6,342 mIU/ml, respectively. Two of the 20 volunteers were positive for HBs at enrollment and had undetectable concentrations of antibody to HBs (#17307 and #17315, Table 3 ). Both of these volunteers acquired detectable antibody to HBs within two weeks of the second dose. After the third dose of the RTS,S/SBAS2 vaccine, their concentrations of antibody to HBs were 14 and 145 mIU/ ml, respectively, although neither cleared their HBs. The HB viral load of these two volunteers remained consistently Ͻ 1 pg/ml (measured on days 0, 42, 166, and 194).
DISCUSSION
Although the sample size was small, our data suggest that the RTS,S/SBAS2 vaccine is safe, well-tolerated, and im-munogenic when given to semi-immune adult men living in a malaria-endemic part of the world. No clinically significant adverse events occurred, symptoms were few, and the vaccine schedule induced brisk increases in antibody concentration to both CSP and HBs.
It has been reported that some volunteers who participated in a clinical trial of the candidate malaria vaccine SPf66 experienced urticaria or other allergic reactions, and some developed local adverse events in the contra-lateral arm following either the second or third doses. 5 Neither of these phenomena occurred during this trial. The most serious local symptom was moderate limitation of arm movement experienced by one volunteer 24 hr after receiving the second dose. This had resolved completely by the following day. One other volunteer experienced a moderate headache that developed within 60 min of receiving the second dose of the RTS,S/SBAS2 vaccine, but this resolved completely within 24 hr.
As expected, the concentration of antibody to the CSP repeat epitope varied considerably among the volunteers before vaccination, the result of differing exposure to malaria in the past. Although plasma concentration of antibody to CSP is not a surrogate marker of protection against P. falciparum malaria, RTS,S/SBAS2 induced brisk antibody responses that were maximal after the third dose of vaccine.
The immunologic correlates of protection against the preerythrocytic stage of P. falciparum are yet to be identified. Yet, the brisk boosting of the pre-existing serologic response against the (NANP) n CSP epitopes and the very high level of humoral responses achieved following the third vaccination could be considered as a surrogate marker of the overall immune response. This would suggest that in this semi-immune population the pre-existing immunity to the P. falciparum parasite does not impair the development of an immune response following vaccination with the RTS,S/ SBAS2 vaccine.
Two of the 20 volunteers were found to be carriers of HBs, but were not excluded from the trial since HBV infection is highly endemic in The Gambia. Neither of them had detectable antibody to HBs at enrollment; both developed antibodies to HBs after the second dose of RTS,S/SBAS2. The remaining volunteers showed marked increases in their concentrations of antibody to HBs in response to RTS,S/ SBAS2 which, again, was maximal after the third dose.
In conclusion, these data demonstrate that the RTS,S/ SBAS2 vaccine is safe, well-tolerated, and immunogenic when given to semi-immune adults living in a malaria-endemic area. The efficacy of this candidate vaccine against a mosquito delivered laboratory challenge with the homologous strain of P. falciparum, combined with the data reported here, supports the need for a trial of this vaccine against natural challenge in the field. Such a trial is currently in progress in The Gambia.
